Bioasis Technologies (BIOAF) 0.8744 $BIOAF
Lysosomal Storage Disorder - Pipeline Review, H1 2014
M2 - Mon Dec 15, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/9z3fm9/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lysosomal Storage Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lysosomal Storage Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lysosomal Storage Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Sangamo BioSciences, Inc. - Neuralstem, Inc. - Amicus Therapeutics, Inc. - Cytomedix, Inc. - AngioChem Inc. - Zymenex A/S - Synageva BioPharma Corp. - Fate Therapeutics, Inc. - to-BBB technologies BV - REGiMMUNE Corporation - biOasis Technologies Inc. - ArmaGen Technologies, Inc. - Orphazyme ApS - Oxyrane Belgium NV - Ultragenyx Pharmaceutical Inc. - Minoryx Therapeutics s.l. For more information visit http://www.researchandmarkets.com/research/9z...al_storage
FATE: 4.90 (+0.23), GEVA: 89.72 (-0.02), SGMO: 14.20 (+0.14), FOLD: 7.94 (+0.06), CUR: 2.70 (+0.07)
Global Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Pipeline Review H2 2014 - Analysis of 9 Companies & 12 Drug Profiles
M2 - Tue Nov 11, 5:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/hphx7p/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Athersys, Inc. - OPKO Health, Inc. - Amicus Therapeutics, Inc. - ReGenX Biosciences, LLC - AngioChem Inc. - PTC Therapeutics, Inc. - Fate Therapeutics, Inc. - biOasis Technologies Inc. - ArmaGen Technologies, Inc. Drug Profiles - ataluren - FT-1050 - MultiStem - AGT-181 - Gene Therapy to Activate Iduronidase for Hurler Syndrome - Oligonucleotide for Mucopolysaccharidosis I - (laronidase Chaperone) - Recombinant Enzyme for Hurler Syndrome - Stem Cell Therapy for Type1 Mucopolysaccharidosis - Cell Therapy for Mucopolysaccharidosis I - Cell Therapy to Activate Iduronidase for Hurler Syndrome - Recombinant Enzyme to Activate Alpha-L-Iduronidase for Mucopolysaccharidosis I For more information visit http://www.researchandmarkets.com/research/hp...saccharido
FATE: 4.90 (+0.23), OPK: 9.63 (+0.21), PTCT: 51.66 (+0.76), ATHX: 1.30 (-0.03), FOLD: 7.94 (+0.06)
Global Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Pipeline Review, H2 2014 - Analysis of 7 Companies & 7 Drug Profiles
M2 - Tue Nov 11, 3:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/nwr23p/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Lentigen Corporation - Shire Plc - Green Cross Corporation - JCR Pharmaceuticals Co., Ltd. - Fate Therapeutics, Inc. - biOasis Technologies Inc. - ArmaGen Technologies, Inc. Drug Profiles - idursulfase - idursulfase - FT-1050 - JR-032 - AGT-182 - LG-1041 - Recombinant Enzyme to Replace Iduronate-2-Sulfatase for Hunter Syndrome For more information visit http://www.researchandmarkets.com/research/nw...saccharido
FATE: 4.90 (+0.23), SHPG: 209.29 (+0.07)
biOasis Engages Willow Tree Group to Assist with Global Business Development Activities
Marketwire - Tue Oct 07, 8:31AM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF) (TSX VENTURE: BTI), the pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier ("BBB"
, engages Willow Tree Capital Group of Toronto, Canada. Willow Tree's full service team of healthcare, scientific and business specialists provides a comprehensive suite of business development services to life science companies worldwide. With its broad transactional experience, Willow Tree specializes in Licensing, strategic consultation and Mergers & Acquisitions services, employing industry-recognized valuation models for life science market value assessments.
BTI.VN: 1.140 (+0.060)
biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation
Marketwire - Thu Sep 18, 8:31AM CDT
BIOASIS TECHNOLOGIES INC. (TSX VENTURE: BTI)(OTCQX: BIOAF), the pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier ("BBB" , announces a study to investigate the ability of its Transcend BBB transport platform technologies to deliver to the Central Nervous System of a knockout animal model, the therapeutic enzyme required to correct the neurological disorder, MPS II, or Hunter Syndrome. The study will be conducted by way of a biOasis grant to the Brains for Brain Foundation ("B4B" of Padova, Italy, headed by renowned Lysosomal Storage Disease expert, Dr. Maurizio Scarpa, Founder and President of the Foundation. The study will be performed at the "Diagnosis and Therapy of Lysosomal Disorders" research facility of the University of Padova, and will be coordinated by Dr. Rosella Tomanin.
BTI.VN: 1.140 (+0.060)
biOasis Advances Its Lysosomal Storage Disease Program with a Knockout Model for Sandhoff Disease
Marketwire - Tue Sep 09, 8:36AM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF)(TSX VENTURE: BTI), announces the commencement of a new phase of its Lysosomal Storage Disease program with a study focused on a knockout model for Sandhoff Disease. The study, to be conducted at The University of British Columbia ("UBC" , will assess the use of therapeutics based on biOasis' proprietary Blood-Brain Barrier vectors, Transcend and Transcend(pep), to correct enzyme deficiencies within the Central Nervous Systems of genetically engineered animals deficient in the enzyme beta-hexosaminidase subunit beta ("HEXB" , which is functionally deficient in sufferers of Sandhoff Disease.
BTI.VN: 1.140 (+0.060)
biOasis Announces NSERC Grant to the University of British Columbia in Support of Collaborative R&D Work with biOasis
Marketwire - Thu Sep 04, 8:04AM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF)(TSX VENTURE: BTI), announces that the Natural Sciences and Engineering Research Council of Canada ("NSERC" has awarded a grant to the University of British Columbia ("UBC" in support of the university's collaborative research and development programs with biOasis Technologies Inc. The University and biOasis continue to develop biOasis' extensive intellectual property relating to Transcend and Transcendpep, protein vectors designed to shuttle existing therapeutic drugs across the Blood-Brain Barrier ("BBB" for the potential treatment of previously untreatable Central Nervous System ("CNS" diseases and conditions.
BTI.VN: 1.140 (+0.060)
biOasis Closes Non-Brokered Private Placement for $1,609,753.15 Gross Proceeds
Marketwire - Fri Aug 29, 5:14PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF) (the "Company" is please to announce it has closed its non-brokered private placement announced on August 8th, 2014. The Company has issued 1,694,447 units (each a "Unit" , including an over allotment of 94,477 Units, at a price of CDN$0.95 per unit, for gross proceeds of CDN$1,609,753.15. Each Unit consists of one common share and one full common share purchase warrant. Each warrant entitles the holder to purchase one additional common share of the Company at a price of CDN$1.20 per share for a period of twelve months up to and including August 29th, 2015, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company's shares are trading at or above a volume weighted average price of $1.40 for 10 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release. A cash finder's fees of CDN$101,460 was paid on a portion of the financing. All securities issued are subject to a hold period of four (4) months and one day and as such may not be traded until December 30th, 2014. The net proceeds from the sale of units have been added to working capital in furtherance of the Company's business.
BTI.VN: 1.140 (+0.060)
WSA Talks to Two Dual-Listed Companies Making Waves
Marketwire - Thu Aug 21, 1:00PM CDT
Wall Street Analyzer's CEO Interview Series
BTI.VN: 1.140 (+0.060)
biOasis issues up to 1.6m units in non-brokered private placement
M2 - Mon Aug 11, 3:29AM CDT
Biopharmaceutical company biOasis Technologies (TSX VENTURE:BTI)(Other OTC:BIOAF) reported on Friday the launch of a non-brokered private placement of up to 1,600,000 units.
BTI.VN: 1.140 (+0.060)
biOasis Announces Non-Brokered Private Placement
Marketwire - Fri Aug 08, 8:10PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF)(the "Company" announces a non-brokered private placement of up to 1,600,000 units (each a "Unit" at a price of $0.95 per Unit of gross proceeds of up to $1,520,000 with an overallotment of up to 20%. Each Unit will consist of one common share and one common share purchase warrant (each a "Warrant" . Each Warrant entitles the holder to purchase one additional common share of the Company at a price of $1.20 per share for a period of twelve months from the date of closing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company's shares are trading at or above a volume weighted average price of $1.40 for 10 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release. Certain directors and officers of the Company intend to acquire the Units under the Private Placement. Any such participation would be considered to be a "related party transaction" as defined under Multilateral Instrument 61 -101 Protection of Minority Security Holders in Special Transactions ("MI 61-101" . The transaction will be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of any shares issued to, or the consideration paid by such persons, will exceed 25% of the Company's market capitalization.
BTI.VN: 1.140 (+0.060)
biOasis Releases Quantitative Results: siRNA-Transcendpep Reduces Target Gene Expression in the Brain
Marketwire - Fri Jul 25, 8:31AM CDT
BIOASIS TECHNOLOGIES INC. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announced on May 6th, 2014, that its newly discovered carrier peptide-Transcendpep-effectively delivered siRNA across the BBB and into brain cells. The company announces that it has achieved effective knock-down of the expression of a target gene in the brain in a sequence-specific manner. Independent analysis of brain tissue revealed that, not only did Transcendpep deliver the siRNA to the brain tissue, but it also reduced the expression of the target gene by 40% to 50% after a single dose.
BTI.VN: 1.140 (+0.060)
biOasis Appoints New Chief Financial Officer and Corporate Secretary
Marketwire - Fri Jun 20, 6:30PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, announces the appointment of Ms. Judi Dalling as its Chief Financial Officer and Corporate Secretary effective immediately. Ms. Dalling is an experienced professional, a graduate of The University of British Columbia Faculty of Law who also has a strong accounting background, having been controller and business manager of a major magazine publishing enterprise for over 20 years. Ms. Dalling currently works with various reporting companies, providing legal, accounting and administration services.
BTI.VN: 1.140 (+0.060)
Lysosomal Storage Disorder - Pipeline Review, H1 2014
M2 - Mon Dec 15, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/9z3fm9/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lysosomal Storage Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lysosomal Storage Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lysosomal Storage Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Sangamo BioSciences, Inc. - Neuralstem, Inc. - Amicus Therapeutics, Inc. - Cytomedix, Inc. - AngioChem Inc. - Zymenex A/S - Synageva BioPharma Corp. - Fate Therapeutics, Inc. - to-BBB technologies BV - REGiMMUNE Corporation - biOasis Technologies Inc. - ArmaGen Technologies, Inc. - Orphazyme ApS - Oxyrane Belgium NV - Ultragenyx Pharmaceutical Inc. - Minoryx Therapeutics s.l. For more information visit http://www.researchandmarkets.com/research/9z...al_storage
FATE: 4.90 (+0.23), GEVA: 89.72 (-0.02), SGMO: 14.20 (+0.14), FOLD: 7.94 (+0.06), CUR: 2.70 (+0.07)
Global Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Pipeline Review H2 2014 - Analysis of 9 Companies & 12 Drug Profiles
M2 - Tue Nov 11, 5:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/hphx7p/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Athersys, Inc. - OPKO Health, Inc. - Amicus Therapeutics, Inc. - ReGenX Biosciences, LLC - AngioChem Inc. - PTC Therapeutics, Inc. - Fate Therapeutics, Inc. - biOasis Technologies Inc. - ArmaGen Technologies, Inc. Drug Profiles - ataluren - FT-1050 - MultiStem - AGT-181 - Gene Therapy to Activate Iduronidase for Hurler Syndrome - Oligonucleotide for Mucopolysaccharidosis I - (laronidase Chaperone) - Recombinant Enzyme for Hurler Syndrome - Stem Cell Therapy for Type1 Mucopolysaccharidosis - Cell Therapy for Mucopolysaccharidosis I - Cell Therapy to Activate Iduronidase for Hurler Syndrome - Recombinant Enzyme to Activate Alpha-L-Iduronidase for Mucopolysaccharidosis I For more information visit http://www.researchandmarkets.com/research/hp...saccharido
FATE: 4.90 (+0.23), OPK: 9.63 (+0.21), PTCT: 51.66 (+0.76), ATHX: 1.30 (-0.03), FOLD: 7.94 (+0.06)
Global Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics Pipeline Review, H2 2014 - Analysis of 7 Companies & 7 Drug Profiles
M2 - Tue Nov 11, 3:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/nwr23p/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Lentigen Corporation - Shire Plc - Green Cross Corporation - JCR Pharmaceuticals Co., Ltd. - Fate Therapeutics, Inc. - biOasis Technologies Inc. - ArmaGen Technologies, Inc. Drug Profiles - idursulfase - idursulfase - FT-1050 - JR-032 - AGT-182 - LG-1041 - Recombinant Enzyme to Replace Iduronate-2-Sulfatase for Hunter Syndrome For more information visit http://www.researchandmarkets.com/research/nw...saccharido
FATE: 4.90 (+0.23), SHPG: 209.29 (+0.07)
biOasis Engages Willow Tree Group to Assist with Global Business Development Activities
Marketwire - Tue Oct 07, 8:31AM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF) (TSX VENTURE: BTI), the pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier ("BBB"
, engages Willow Tree Capital Group of Toronto, Canada. Willow Tree's full service team of healthcare, scientific and business specialists provides a comprehensive suite of business development services to life science companies worldwide. With its broad transactional experience, Willow Tree specializes in Licensing, strategic consultation and Mergers & Acquisitions services, employing industry-recognized valuation models for life science market value assessments. BTI.VN: 1.140 (+0.060)
biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation
Marketwire - Thu Sep 18, 8:31AM CDT
BIOASIS TECHNOLOGIES INC. (TSX VENTURE: BTI)(OTCQX: BIOAF), the pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier ("BBB"
, announces a study to investigate the ability of its Transcend BBB transport platform technologies to deliver to the Central Nervous System of a knockout animal model, the therapeutic enzyme required to correct the neurological disorder, MPS II, or Hunter Syndrome. The study will be conducted by way of a biOasis grant to the Brains for Brain Foundation ("B4B" of Padova, Italy, headed by renowned Lysosomal Storage Disease expert, Dr. Maurizio Scarpa, Founder and President of the Foundation. The study will be performed at the "Diagnosis and Therapy of Lysosomal Disorders" research facility of the University of Padova, and will be coordinated by Dr. Rosella Tomanin. BTI.VN: 1.140 (+0.060)
biOasis Advances Its Lysosomal Storage Disease Program with a Knockout Model for Sandhoff Disease
Marketwire - Tue Sep 09, 8:36AM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF)(TSX VENTURE: BTI), announces the commencement of a new phase of its Lysosomal Storage Disease program with a study focused on a knockout model for Sandhoff Disease. The study, to be conducted at The University of British Columbia ("UBC"
, will assess the use of therapeutics based on biOasis' proprietary Blood-Brain Barrier vectors, Transcend and Transcend(pep), to correct enzyme deficiencies within the Central Nervous Systems of genetically engineered animals deficient in the enzyme beta-hexosaminidase subunit beta ("HEXB" , which is functionally deficient in sufferers of Sandhoff Disease. BTI.VN: 1.140 (+0.060)
biOasis Announces NSERC Grant to the University of British Columbia in Support of Collaborative R&D Work with biOasis
Marketwire - Thu Sep 04, 8:04AM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF)(TSX VENTURE: BTI), announces that the Natural Sciences and Engineering Research Council of Canada ("NSERC"
has awarded a grant to the University of British Columbia ("UBC" in support of the university's collaborative research and development programs with biOasis Technologies Inc. The University and biOasis continue to develop biOasis' extensive intellectual property relating to Transcend and Transcendpep, protein vectors designed to shuttle existing therapeutic drugs across the Blood-Brain Barrier ("BBB" for the potential treatment of previously untreatable Central Nervous System ("CNS" diseases and conditions. BTI.VN: 1.140 (+0.060)
biOasis Closes Non-Brokered Private Placement for $1,609,753.15 Gross Proceeds
Marketwire - Fri Aug 29, 5:14PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF) (the "Company"
is please to announce it has closed its non-brokered private placement announced on August 8th, 2014. The Company has issued 1,694,447 units (each a "Unit" , including an over allotment of 94,477 Units, at a price of CDN$0.95 per unit, for gross proceeds of CDN$1,609,753.15. Each Unit consists of one common share and one full common share purchase warrant. Each warrant entitles the holder to purchase one additional common share of the Company at a price of CDN$1.20 per share for a period of twelve months up to and including August 29th, 2015, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company's shares are trading at or above a volume weighted average price of $1.40 for 10 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release. A cash finder's fees of CDN$101,460 was paid on a portion of the financing. All securities issued are subject to a hold period of four (4) months and one day and as such may not be traded until December 30th, 2014. The net proceeds from the sale of units have been added to working capital in furtherance of the Company's business. BTI.VN: 1.140 (+0.060)
WSA Talks to Two Dual-Listed Companies Making Waves
Marketwire - Thu Aug 21, 1:00PM CDT
Wall Street Analyzer's CEO Interview Series
BTI.VN: 1.140 (+0.060)
biOasis issues up to 1.6m units in non-brokered private placement
M2 - Mon Aug 11, 3:29AM CDT
Biopharmaceutical company biOasis Technologies (TSX VENTURE:BTI)(Other OTC:BIOAF) reported on Friday the launch of a non-brokered private placement of up to 1,600,000 units.
BTI.VN: 1.140 (+0.060)
biOasis Announces Non-Brokered Private Placement
Marketwire - Fri Aug 08, 8:10PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF)(the "Company"
announces a non-brokered private placement of up to 1,600,000 units (each a "Unit" at a price of $0.95 per Unit of gross proceeds of up to $1,520,000 with an overallotment of up to 20%. Each Unit will consist of one common share and one common share purchase warrant (each a "Warrant" . Each Warrant entitles the holder to purchase one additional common share of the Company at a price of $1.20 per share for a period of twelve months from the date of closing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company's shares are trading at or above a volume weighted average price of $1.40 for 10 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release. Certain directors and officers of the Company intend to acquire the Units under the Private Placement. Any such participation would be considered to be a "related party transaction" as defined under Multilateral Instrument 61 -101 Protection of Minority Security Holders in Special Transactions ("MI 61-101" . The transaction will be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of any shares issued to, or the consideration paid by such persons, will exceed 25% of the Company's market capitalization. BTI.VN: 1.140 (+0.060)
biOasis Releases Quantitative Results: siRNA-Transcendpep Reduces Target Gene Expression in the Brain
Marketwire - Fri Jul 25, 8:31AM CDT
BIOASIS TECHNOLOGIES INC. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announced on May 6th, 2014, that its newly discovered carrier peptide-Transcendpep-effectively delivered siRNA across the BBB and into brain cells. The company announces that it has achieved effective knock-down of the expression of a target gene in the brain in a sequence-specific manner. Independent analysis of brain tissue revealed that, not only did Transcendpep deliver the siRNA to the brain tissue, but it also reduced the expression of the target gene by 40% to 50% after a single dose.
BTI.VN: 1.140 (+0.060)
biOasis Appoints New Chief Financial Officer and Corporate Secretary
Marketwire - Fri Jun 20, 6:30PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, announces the appointment of Ms. Judi Dalling as its Chief Financial Officer and Corporate Secretary effective immediately. Ms. Dalling is an experienced professional, a graduate of The University of British Columbia Faculty of Law who also has a strong accounting background, having been controller and business manager of a major magazine publishing enterprise for over 20 years. Ms. Dalling currently works with various reporting companies, providing legal, accounting and administration services.
BTI.VN: 1.140 (+0.060)
